Baseline characteristics of patients with non-Hodgkin lymphoma
| Characteristics . | Non-Hodgkin lymphoma (n = 104) . |
|---|---|
| Age (y)* | 51 (range, 14-73) |
| Sex (%) | |
| Male | 60.6 |
| Female | 39.4 |
| Histology (%) (REAL classification) | |
| Diffuse large cell | 50 |
| Follicular large cell | 28 |
| Peripheral T cell | 8 |
| Anaplastic T cell | 6 |
| T-rich B cell | 3 |
| Angiocentric T cell | 3 |
| Angiocentric B cell | 1 |
| Natural killer cell | 1 |
| Disease status at transplantation (%) | |
| First relapse | 7.7 |
| Progression | 0.9 |
| Partial response | 68.3 |
| Complete response | 23.1 |
| Prognostic factors for NHL (%) | |
| Age ≥ 60 | 32 |
| LDH level > normal for age/sex | 57.7 |
| Performance status ≥ 2 | 7.7 |
| Extranodal sites ≥ 2 | 6.7 |
| Stage III/IV disease | 66 |
| Stem cell source (%) | |
| BM | 47.1 |
| PBSC | 50.9 |
| Both | 2 |
| Platelet level > 20 × 109/L (%) | 71.1 |
| ALC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 53.8 |
| < 500 cells/μL | 46.2 |
| ANC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 84 |
| < 500 cells/μL | 16 |
| Characteristics . | Non-Hodgkin lymphoma (n = 104) . |
|---|---|
| Age (y)* | 51 (range, 14-73) |
| Sex (%) | |
| Male | 60.6 |
| Female | 39.4 |
| Histology (%) (REAL classification) | |
| Diffuse large cell | 50 |
| Follicular large cell | 28 |
| Peripheral T cell | 8 |
| Anaplastic T cell | 6 |
| T-rich B cell | 3 |
| Angiocentric T cell | 3 |
| Angiocentric B cell | 1 |
| Natural killer cell | 1 |
| Disease status at transplantation (%) | |
| First relapse | 7.7 |
| Progression | 0.9 |
| Partial response | 68.3 |
| Complete response | 23.1 |
| Prognostic factors for NHL (%) | |
| Age ≥ 60 | 32 |
| LDH level > normal for age/sex | 57.7 |
| Performance status ≥ 2 | 7.7 |
| Extranodal sites ≥ 2 | 6.7 |
| Stage III/IV disease | 66 |
| Stem cell source (%) | |
| BM | 47.1 |
| PBSC | 50.9 |
| Both | 2 |
| Platelet level > 20 × 109/L (%) | 71.1 |
| ALC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 53.8 |
| < 500 cells/μL | 46.2 |
| ANC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 84 |
| < 500 cells/μL | 16 |
REAL indicates revised European-American lymphoma; NHL, non-Hodgkin lymphoma; for other abbreviations, see Table 1.
Years expressed as the median of the group.